Toxicokinetic behaviors and modes of perfluorooctane sulfonate (PFOS) and perfluorooctane acid (PFOA) on tilapia (Oreochromis niloticus) by Han, ZX et al.
African Journal of Biotechnology Vol. 10(60), pp. 12943-12950, 5 October, 2011     
Available online at http://www.academicjournals.org/AJB 
DOI: 10.5897/AJB11.1767 





Full Length Research Paper 
 
Toxicokinetic behaviors and modes of perfluorooctane 
sulfonate (PFOS) and perfluorooctane acid (PFOA)  
on tilapia (Oreochromis niloticus) 
 
Zhao-Xiang Han1*, Meng Zhang1 and Chun-Xia Lv 2 
 
1
School of Chemical Engineering, Huaihai Institute of Technology, Lianyungang, Jiangsu, 222005, China. 
2
Jiaonan Agricultural Bureau, Qingdao, Shandong, 266400, China. 
 
Accepted 7 September, 2011 
 
Perfluorooctane sulfonate (PFOS) and perfluorooctane acid (PFOA) are widely distributed 
environmentally persistent organic pollutants found at low levels in human and wildlife ecosystem. The 
objectives of the current study were to investigate toxicokinetic behaviors and modes of PFOS and 
PFOA on tilapia (Oreochromis niloticus). The toxicokinetic behaviors and modes of PFOS and PFOA are 
different in tilapia during experimental periods. Exposure to both PFOS and PFOA was approximately 5 
to 6 times higher for male tilapia than for female tilapia. The terminal half-life of PFOA in serum was 
about 4 times longer for male tilapia than for female tilapia. The apparent volume of distribution for 
PFOS and PFOA in the serum was about 3 to 4 times higher for female tilapia than for male tilapia. The 
lymphocytes level decreased rapidly with the increased PFOA concentration. A similar pattern was 
observed with the PFOS exposure, and it is remarkable that PFOS and PFOA were significantly 
accumulated in both PFOS and PFOA exposure but PFOA showed a greater effect than PFOS. PFOA 
blood concentrations were lesser than the limit of quantification in non-exposure tilapia during an 
uptake period, while measured PFOS concentrations were at least six times lesser than those in PFOS 
exposure. Tilapia weight gain was also decreased with statistical significance in all PFOA-treated 
groups, and the effect of PFOA was higher than that of PFOS. The effects of PFOA in survival percent 
were more pronounced in this case than that of PFOS. Moreover, PFOA had similar mode, and PFOS 
and PFOA can inhibit the 17β-HSD3 enzyme activity of tilapia. 
 






Many products of perfluorinated compounds (PFCs) are 
becoming ubiquitous in human and wildlife environment 
because of the continuous use of such products (Giesy 
and Kannan, 2002; Olsen et al., 2005) and the two PFCs 
that have received the greatest attention are 
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acid (PFOA). In a monitoring study of human serum 
PFOS was determined collected from the general public, 
to be the most abundant PFC followed by PFOA (Kannan 
et al., 2004). While exposure pathways of PFOA and 
PFOS to humans and aquaculture have not yet been fully 
elucidated, the consumption of fish (Falandysz et al., 
2006) and farm animals (Guruge et al., 2005) have been 
suggested as major contributors of PFOS and PFOA to 
exposed human populations.  
A few pharmacokinetic studies with PFOA or PFOS 
have been conducted with mammals such as rats, dogs 
and monkeys (Seacat et al., 2002; Kudo et al., 2002; Lau 
et al., 2004), but, the details of the toxicokinetic profile 
and modes of PFOS and PFOA have not  been published  




with aquatic animals. PFOS and PFOA are readily 
absorbed and are poorly eliminated from blood and other 
tissues with biological half-time for depuration that can 
range from several weeks to months, depending on the 
species and sex. Previously, it has been reported that 
repeated dose toxicity with PFOS and PFOA in mice, rats 
and monkeys (Seacat et al., 2002, 2003; Luebker et al., 
2005; Thibodeaux et al., 2003; Lau et al., 2003) have 
shown that body burden is proportional to cumulative 
dose at lower and moderate experimental doses.  
To control effectively the exposures to PFOS and 
PFOA, it is necessary to understand the kinetic 
mechanism and metabolism of PFOS and PFOA in the 
environment. Therefore, the objective of our study was to 
explore the toxicokinetic behaviors and modes of PFOS 
and PFOA in tilapia and evaluate if the pharmacokinetic 
profile and modes of PFOS and PFOA are similar to 
tilapia after oral administration. 
 
 




A total of 60 freshwater tilapia (Oreochromis niloticus) 20 to 30 g 
each (30 females and 30 males) were collected from a local fish 
farm at the industrial and agricultural areas. They were kept in a 
300 L fiber-glass tank with recirculating water for 3 weeks (22 ± 
0.5°C, 12 h light / 12 h dark cycles). Tilapia were randomly divided 
into three groups (sex for each group) in which they were treated 
with PFOS and PFOA in the form of pelleted dry feed at a dose of 
0, 1.0, 5.0 and 10.0 mg/L, respectively for 24, 48, 72, 96, 120, and 
144 h.  
The fish were fed once every other day with commercial fish 
food. Doses applied in this study were designed based on the 
pharmacological and toxicological studies, and PFOS and PFOA 
were found to be effective at range of 1 to 20 mg/g. The fish were 
then killed immediately by a blow on the head and samples of the 




Sample preparation and analysis 
 
Blood samples were collected with an ion-pairing method with some 
modifications (Kannan et al., 2004). Measurement of PFOS and 
PFOA in blood or tissues was conducted using HPLC with high 
resolution and electro-spray tandem mass spectrometry (HPLC-
MS/MS). Serum was prepared by standard methods. Serum 
samples were stored frozen (−20°C) until analysis using a validated 
HPLC-MS/MS method. Hemolymphs were instantly mixed with the 
same volume of ACD (1.5% citric acid, 2.5% trisodium citrate, 2% 
D-glucose) solution, and were kept frozen at −70°C. Hemolymph 
were thawed and vortexed to assure homogeneity before 
extraction.  
0.5 ml of hemolymph were placed into 10 ml polypropylene 
centrifuge, then 7.0 ml of the extraction solution (1 M HCl 
acetonitrile (4/500, v/v) was add. The tubes were vortexed for 2 min 
and centrifuged at 8000 rpm for 10 min and 4°C. The resulting clear 
supernatant was dried using a vortex evaporator and reconstituted 
in 1.0 ml of mobile phase. After filtration with 0.45 µm disposable 
syringe (filter units equipped with cellulose acetate membranes), 






Preparation of microsomal protein and 17β-HSD3 activity 
assay 
 
Microsomal preparations of human and rat testes were done as 
described previously (Hu et al., 2009). Microsomal protein 
concentrations were adjusted to 4 mg/ml and used for 
measurement of 17β-HSD3 activities. 17β-HSD3 activity in 
spermary microsomes was recorded using the normal procedures 





All pharmacokinetic parameters were calculated using non-
compartmental analysis from the individual concentrations of PFOS 
and PFOA in serum for tilapia and from the mean concentrations in 
serum, lymphocytes and blood. The data could not be consistently 
fit to a one-compartment model using WinNonlin version 5.2 
(Pharsight Corporation, Mountain View, CA). The program used a 
compartmental open model based on non-linear regression analysis 
and a non-compartmental analysis based on statistical moment 





Assays were repeated three times. The IC50 was calculated using 
GraphPad version 4.0 using nonlinear regression of curve fit with 
one-site competition. Data were subjected to analysis by one-way 
ANOVA followed by Duncan multiple comparison test to identify 
significant differences between groups when three groups were 
calculated. All data were expressed as means ± SEM. Differences 
were regarded as significant at P<0.05.  
 
 
RESULTS AND DISCUSSION 
 
Toxicokinetic behaviors of PFOS and PFOA in serum 
 
The serum concentrations of PFOS and PFOA following 
oral administration dose of 5 mg/g are illustrated in Figure 
1. Systemic exposures to PFOA were approximately 2 to 
3 times higher than exposures to PFOS at equivalent 
dosages. This is partially due to a terminal half-life for 
PFOS that is shorter than that for PFOA. Exposure to 
both PFOS and PFOA was approximately 5 to 6 times 
higher for male tilapia than for female tilapia, this may be 
attributable to several related factors such as the shorter 
half-life, higher apparent clearance and higher distribution 
numbers of females than for males.  
The terminal half-life of PFOS in serum was appro-
ximately 2-fold shorter for female tilapia (1.0 h) than for 
male tilapia (2.0 h). The terminal half-life of PFOA in 
serum was about 4-fold longer for male tilapia (1.4 h) 
than female tilapia (0.35 h). Apparent clearance of PFOS 
and PFOA from the serum was roughly 5 to 6 times 
higher for female tilapia than for male tilapia. The 
apparent volume of distribution for PFOS and PFOA in 
the serum was about 3 to 4 times higher for female tilapia 
than for male tilapia. Lower apparent volumes of 
distribution for both female and male may reflect rapid 
clearance, including protein binding, and elimination.  
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Figure 1. Mean concentrations (±S.E.) of PFOS and PFOA in serum of male and female tilapia following oral 




The serum concentrations of PFOS and PFOA followed 
repeated oral doses of 10 mg/g, respectively for male and 
female tilapia. Oral administration of PFOS and PFOA 
resulted in systemic exposure, which was proportional to 
the dosage level. Exposure tended to decrease upon 
repeated dosing. The terminal half-life of PFOS and 
PFOA in serum, however, was about 1 to 2 h regardless 
of dosage level, gender or number of doses. Studies with 
PFOS and PFOA in rats have demonstrated a sex-
specific difference in elimination, with females more 
actively excreting these materials via the kidney than 
males (USEPA OPPTS, 2002; Vanden Heuval et al., 
1991). This difference contributes to large differences in 
toxicokinetic behavior. For example, Vanden Heuval et al. 
(1991) reported that the half-life for 
14
C-PFOA was 9 days 
for male rats and 4 h for female rats. Ylinen at al. (1990) 
reported a half-life of 24 h in female and 105 h in males 
Wistar rats. In the study, there was also appreciable 
gender difference in the half-life of PFOS and PFOA in 
serum of tilapia following oral doses. 
 
 
Toxicokinetic behaviors of PFOS and PFOA in 
peripheral lymphocytes  
 
The PFOS and PFOA concentration-time curves for the 
tests showed instant absorption followed by distribution 
phase as shown in Figure 2. After an oral administration 
of 5.0 mg/g body weight of tilapia, the peripheral 
lymphocytes PFOA concentration peaked at 600.09 ± 
15.8 ng/ml at the first sampling time of 24 h and then the 
lymphocytes PFOA concentration decreased rapidly from 
600.09 ± 15.8 to 468.32 ± 12.6 ng/ml post-treatment. A 
second absorption peak (480.65 ± 9.5 ng/ml) was 
observed at 96 h post administration, after which the 
PFOA concentration declined slowly and continuously 
until the end of the experiment. A similar pattern and 
dosage was observed with the PFOS exposure, including 
a peak lymphocytes PFOS concentration of 453.0 ± 8.6 
ng/ml at the first sampling time of 24 h and a second 
absorption peak (385.78 ± 11.4 ng/ml) at 72 h post-
treatment.  
It is possible that there is recirculation of PFOS and 
PFOA, resulting in second absorption peaks. The 
lymphocytes PFOS and PFOA concentration at 5.0 mg/g 
dosage body weight were analyzed with pharma-
cokinetics software (DAS ver 1.0), and both could be 
described by a two compartment open model with first-
order absorption. Both the absorption half-time (T1/2Ka) 
and the lag time before initiation of absorption (Tlag) were 
approximately zero. With respect to apparent volume of 
distribution and total body clearance, no significant 
differences were observed between PFOS and PFOA. 
The distribution rate constant (α) of PFOS in lymphocytes 
was approximately 1.5-fold lesser than for PFOA, and the 
elimination rate constant (β) of PFOS in lymphocytes was 
about 2-fold higher than for PFOA. After non-
compartment  model  analysis,  the  value  of  area  under  












































Figure 2. Peripheral lymphocytes concentrations of PFOS and PFOA in tilapia following oral administration at 




the peripheral lymphocytes concentration-time curve 
(AUC0-∞) for PFOA was 2-fold that of the lymphocytes 
PFOS concentration. It is remarkable that PFOS and 
PFOA were significantly accumulated in our study in both 
PFOS and PFOA exposure, with PFOA showing a greater 
effect than PFOS. Similar results have been observed in 
few fishes, such as the zebrafish (Huang et al., 2010) and 
common carp (Cyprinus carpio) (Hoff et al., 2003a).  
 
 
Uptake and elimination behaviors of PFOS and PFOA 
in blood 
 
A one-compartment model was used to describe the 
elimination behavior of PFOS or PFOA from blood in 
tilapia according to the equation: in (Ct/C0)=-kt, where Ct 
is the concentration of PFOS or PFOA at the time (t) in an 
elimination phase, C0 is the concentration at the onset of 
depuration (ng/mL) and k is the elimination rate constant. 
The time-course concentrations of PFOS and PFOA 
released from oral administration of different uptake 
profiles in tilapia blood over an exposure period was 
recorded. The maximum PFOS and PFOA concentrations 
in blood taken from same dosage treatment were 7.3 × 
103 and 9.6 × 103 ng/ml at primary exposure time (24 h), 
respectively (Figure 3).   
Subsequently, introduced PFOS fluctuated over 72 h 
uptake period, while PFOA in 5.0 mg/ml treatment had an 
increase at 24 h followed by decreased blood levels in 
later exposure periods. PFOA blood concentrations were 
lesser than the limit of quantification in non-exposure 
tilapia during an uptake period, while measured PFOS 
concentrations were at least six times lesser than those 
in PFOS exposure. Concentrations of PFOS and PFOA in 
blood reflected the dose from oral administration target 
PFCs. Nevertheless, elimination rates of PFOS and 
PFOA from blood of tilapia were significantly different 
(Figure 3). Concentrations of PFOS  in  blood  decreased 
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Figure 3. Changes in the blood concentrations of PFOA or PFOS in tilapia following oral administration at 5.0 mg/g 




rapidly during the depuration phase, with PFOS concen-
trations at the termination of depuration being 56 to 59% 
as compared to those at the beginning of depuration. 
However, only 18 to 23% reduction of PFOA was 
eliminated from the blood during the same exposure 
period. The elimination half-time (t1/2) of treatment-
averaged PFOS (10.6 h) was almost four-fold more than 
that of treatment-averaged PFOA (42.5 h). The 
elimination rate constant of PFOS and PFOA was 0.12 ± 
0.01 and 0.03 ± 0.002 h
-1 
with the same dosage, 
respectively. Concentrations of PFOS and PFOA were 
similar during the depuration period to those measured 
during the exposure period in control group. Different 
elimination kinetics were observed even though PFOS 
and PFOA are structurally similar anionic surfactants that 
possess some similar physico-chemical properties such 
as pKa, Henry’s Law constant, and similar hydrophobicity 
based on critical micelle concentration (Giesy and 
Kannan, 2002; Kissa, 2001).  
 
 
Dose-response modes of PFOS and PFOA on weight 
and percent survival 
 
We chose 144 h as the standard incubation time for the 
experiments according to the primary experiment. Tilapia 
weights, as an average of each experiment group, are 
presented in Figure 4A and were decreased with 
statistical significance in all PFOS-treated groups. Tilapia 
weight gains were also decreased with statistical 
significance in all PFOA-treated groups, and the effect of 
PFOA was higher than that of PFOS. It appears that 
there is positive dependence between PFOS and PFOA 
concentration and tilapia weight to PFOS and PFOA 
exposure environment, represented with a high 
coefficient of correlation (p = 0.021, R = 0.9316 for PFOS 
and R = 0.9258 for PFOA). Figure 4B presents data for 
the mean percent of tilapia that survived in each 
experiment group. The mean percent survival of live born 
tilapia was decreased in a dose-dependent manner and 
became statistically significant in the 5.0 and 10.0 mg/l 
oral administration dose groups for PFOS-treated groups. 
The mean percent survival of live tilapia decreased from 
88 to 26% with 0 and 10.0 mg/L PFOA exposure, 
respectively. Furthermore, the effects of PFOA in percent 
survival were more pronounced in this case than that of 
PFOS. Multiple linear regression analysis revealed a 
significant correlation between PFOS and PFOA 
concentration and survival (p = 0.011, R = 0.9056 for 
PFOS and R = 0.9403 for PFOA). 
 
 
Inhibition modes of PFOS and PFOA on 17β-HSD3 
activity 
 
17β-HSD3 levels were determined only in male tilapia. 
Activity of the  17β-HSD3  enzyme,  which  catalyzes  the  
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Figure 4. Mean weight (A) and mean percent survival (B) of tilapia treated with PFOS or 
PFOA. Error bars represent 95% confidence limits. Modeled dose–response curves are 
drawn based on the equation shown, and means that are statistically different from control 




conversion of androstenedione to testosterone, was 
measured in male tilapia spermary microsomes in the 
presence of PFOS and PFOA exposure. Figure 5 shows 
the effect of PFOS and PFOA on 17β-HSD3 activities 
when tested at different concentrations, respectively. 17β-
HSD3 activity was strongly reduced  by  PFOS,  which  is  
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Figure 5. The inhibition of PFOS or PFOA on male tilapia 17β-HSD3 activities in testicular microsome (mean ± 




also in a dose-dependent manner. The activities of the 
tilapia 17β-HSD3 enzymes in the absence of PFOS were 
determined to be 5.36 ± 0.06 nmol/mg protein/min. PFOS 
inhibited the tilapia 17β-HSD3 enzyme by 15, 60 and 
88% as compared to control at the oral dose of 1.0, 5.0, 
and 10.0 mg/L, respectively. Moreover, PFOA had similar 
mode, PFOA inhibited the tilapia 17β-HSD3 enzyme by 
23, 75 and 93% as compared to control at the oral dose 
of 1.0, 5.0, and 10.0 mg/L, respectively. The IC50 for 
PFOS and PFOA in the inhibition of tilapia 17β-HSD3 
activity were determined to be 4.18 ± 0.05 and 5.33 ± 
0.02, whereas the IC50 of PFOS and PFOA in the 
inhibition of tilapia 17β-HSD3 activity were 102 and 106 
nmol/mg protein min, respectively as previously reported 
(Chu et al., 2009). The mode of PFOS and PFOA 
inhibition of tilapia 17β-HSD3 activity differs from that 
previously reported for the rat enzyme in and PFOS and 
PFOA inhibited rat 17β-HSD3 activity with competitive 
inhibition on substrate DIONE binding site and 
noncompetitive inhibition on cofactor NADPH binding site 
of the enzyme (Zhao et al., 2010; Chu et al., 2009). The 
biological roles of 11β-HSD2 in fish are complex. 11β-
HSD2 is expressed in fish liver, kidney, brain and 
reproductive organs (Michael and Baker, 2004; Zhao et 
al., 2010). 11β-HSD2 and 17β-HSD3 catalyzes the 
conversion of 11β-hydroxytestosterone and androstene-
dione to 11-keto-testosterone, a fish androgen, consistent 
with the presence of 11β-HSD2 and 17β-HSD3 in 
gonads. Fish 11β-HSD2 and 17β-HSD3 are expressed in 
testis (Michael and Baker, 2004; Zhao et al., 2010), 






The results present in this study showed that though they 
are structurally similar, the toxicokinetic behaviors and 
modes of PFOS and PFOA are different in tilapia during 
experimental periods. The toxicokinetics behaviors and 
modes of PFOS and PFOA were estimated after oral 
administration to the tilapia. Systemic exposures to PFOA 
were approximately 2 to 3 times higher than exposures to 
PFOS at equivalent dosages; this is partially due to a 
terminal half-life for PFOS that is shorter than that for 
PFOA. Exposure to both PFOS and PFOA was 
approximately 5 to 6 times higher for male tilapia than for 
female tilapia. The terminal half-life of PFOA in serum 
was about 4 times longer for male tilapia than female 
tilapia. The apparent volume of distribution for PFOS and 
PFOA in the serum was about 3 to 4 times higher for 
female tilapia than for male tilapia. Lower apparent 
volumes of distribution for both female and male may 
reflect rapid clearance, including protein binding and 
elimination. After an oral administration of 5.0 mg/g body 
weight   of   tilapia,   the  peripheral   lymphocytes   PFOA  




concentration peaked at 600.09 ± 15.8 ng/ml at the first 
sampling time of 24 h and then the lymphocytes PFOA 
concentration decreased rapidly from 600.09 ± 15.8 to 
468.32 ± 12.6 ng/ml post-treatment. A similar pattern was 
observed with the PFOS exposure. With respect to 
apparent volume of distribution and total body clearance, 
no significant differences were observed between PFOS 
and PFOA. The distribution rate constant (α) of PFOS in 
lymphocytes was approximately 1.5 times lesser than for 
PFOA, and the elimination rate constant (β) of PFOS in 
lymphocytes was about 2 times higher than for PFOA. It 
is remarkable that PFOS and PFOA were significantly 
accumulated in both PFOS and PFOA exposure, with 
PFOA showing a greater effect than PFOS. PFOA blood 
concentrations were lesser than the limit of quantification 
in non-exposure tilapia during an uptake period, while 
measured PFOS concentrations were at least six times 
lesser than those in PFOS exposure. Tilapia weight gains 
were also decreased with statistical significance in all 
PFOA-treated groups, and the effect of PFOA was higher 
than that of PFOS. The effects of PFOA on percent 
survival were more pronounced than that of PFOS. 
Moreover, PFOS and PFOA can inhibit the 17β-HSD3 
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